drugset
Drugs / apolizumab
last change Mar 2017 re-read 3 minutes ago

apolizumab

also known as HU-1D10 · Remitogen · Remitogen smart1d10

Monoclonal antibody

Developed for
chronic lymphocytic leukemia/small lymphocytic lymphoma · lymphoma · acute myeloid leukemia · diffuse large B-cell lymphoma · follicular lymphoma · mantle cell lymphoma
Investigated by
National Cancer Institute (NCI) · PDL BioPharma, Inc. · Stanford University

Trials 6

today NCT00089154 · Ph 2 NCT00055783 · Ph 2 NCT00022971 · Ph 1 NCT00017472 · Ph 1 NCT00014664 · Ph 2 NCT00004101 · Ph 1
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT00022971 Aug 2001 → Jan 2010 chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma National Cancer Institute (NCI) Terminated No outcome recorded
Phase 1 NCT00017472 Apr 2001 → Apr 2006 MALT lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, nodal marginal zone B-cell lymphoma +1 National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00004101 Nov 1999 → Jun 2005 lymphoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 23 trials
Phase 2 NCT00089154 Aug 2004 → Oct 2005 chronic lymphocytic leukemia/small lymphocytic lymphoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00055783 Jul 2002 → Apr 2003 lymphoma Stanford University Completed No outcome recorded
Phase 2 NCT00014664 Oct 2000 → ? lymphoma PDL BioPharma, Inc. Unknown No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as apolizumab ClinicalTrials.gov intervention name — accepted as the source's own label NCT00017472 ↗
5

NCT00089154 ↗

NCT00022971 ↗

NCT00004101 ↗

NCT00055783 ↗

NCT00014664 ↗
Known as HU-1D10 ChEMBL registry synonym — accepted as the source's own label CHEMBL2108252 ↗
Known as Remitogen ChEMBL registry synonym — accepted as the source's own label CHEMBL2108252 ↗
Known as Remitogen smart1d10 ChEMBL registry synonym — accepted as the source's own label CHEMBL2108252 ↗
Modality Monoclonal antibody “monoclonal antibody Hu1D10 (apolizumab)” NCT00017472 ↗
Route Intravenous “Patients receive apolizumab IV over at least 2 hours” NCT00017472 ↗